We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+12.73%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$362M
AUM Growth
-$26.1M
Cap. Flow
-$33.3M
Cap. Flow %
-9.19%
Top 10 Hldgs %
27.18%
Holding
180
New
35
Increased
46
Reduced
71
Closed
24

Top Buys

1
ABVX
Abivax
ABVX
+$4.86M
2
NRIX icon
Nurix Therapeutics
NRIX
+$3.76M
3
IVA
Inventiva
IVA
+$3.75M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.21M
5
DFTX
Definium Therapeutics
DFTX
+$3.15M

Top Sells

1
VRDN icon
Viridian Therapeutics
VRDN
+$7.08M
2
COGT icon
Cogent Biosciences
COGT
+$5.16M
3
RVMD icon
Revolution Medicines
RVMD
+$5.14M
4
CDTX
Cidara Therapeutics
CDTX
+$5.06M
5
ACLX
Arcellx
ACLX
+$4.89M

Sector Composition

1 Healthcare 66.93%
2 Technology 9.01%
3 Industrials 5.47%
4 Consumer Discretionary 2.89%
5 Financials 2.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XOMA
76
DELISTED
Xoma
XOMA
$1.47M 0.41%
46,814
-66,103
-59% -$1.77M
AVTR icon
77
Avantor
AVTR
$7.56B
$1.46M 0.4%
+186,500
New +$1.84M
MA icon
78
Mastercard
MA
$480B
$1.46M 0.4%
2,924
+140
+5% +$73.7K
RYTM icon
79
Rhythm Pharmaceuticals
RYTM
$7.31B
$1.46M 0.4%
16,796
-26,071
-61% -$2.54M
KBR icon
80
KBR
KBR
$4.45B
$1.45M 0.4%
39,406
+9,400
+31% +$386K
RBC icon
81
RBC Bearings
RBC
$18.2B
$1.45M 0.4%
2,663
-40
-1% -$21.2K
MIRM icon
82
Mirum Pharmaceuticals
MIRM
$7.25B
$1.44M 0.4%
+15,563
New +$1.46M
U icon
83
Unity
U
$12.7B
$1.38M 0.38%
62,763
+34,100
+119% +$946K
SVRA icon
84
Savara
SVRA
$1.13B
$1.37M 0.38%
+250,999
New +$1.4M
MDGL icon
85
Madrigal Pharmaceuticals
MDGL
$12.8B
$1.36M 0.38%
2,598
-241
-8% -$115K
CTMX icon
86
CytomX Therapeutics
CTMX
$788M
$1.35M 0.37%
288,057
+94,116
+49% +$478K
CGON icon
87
CG Oncology
CGON
$6.34B
$1.35M 0.37%
19,914
-9,411
-32% -$533K
TDG icon
88
TransDigm Group
TDG
$67.9B
$1.33M 0.37%
1,145
-1,030
-47% -$1.35M
ASND icon
89
Ascendis Pharma A/S
ASND
$17.1B
$1.32M 0.37%
5,781
+2,121
+58% +$475K
KNX icon
90
Knight Transportation
KNX
$12.5B
$1.32M 0.36%
+22,900
New +$1.31M
RKT icon
91
Rocket Companies
RKT
$41.1B
$1.32M 0.36%
92,430
-5,000
-5% -$91K
INTU icon
92
Intuit
INTU
$79.6B
$1.3M 0.36%
3,003
+1,190
+66% +$568K
MU icon
93
Micron Technology
MU
$959B
$1.28M 0.35%
+3,800
New +$1.49M
BLTE
94
Belite Bio
BLTE
$6.02B
$1.28M 0.35%
+8,033
New +$1.35M
MLYS icon
95
Mineralys Therapeutics
MLYS
$2.39B
$1.27M 0.35%
46,778
-77,766
-62% -$2.28M
JHX icon
96
James Hardie Industries
JHX
$15B
$1.24M 0.34%
+65,598
New +$1.48M
APH icon
97
Amphenol
APH
$186B
$1.24M 0.34%
9,781
+2,700
+38% +$380K
BKNG icon
98
Booking.com
BKNG
$141B
$1.19M 0.33%
7,075
+1,000
+16% +$184K
KRC icon
99
Kilroy Realty
KRC
$4.68B
$1.18M 0.33%
+41,997
New +$1.38M
MTZ icon
100
MasTec
MTZ
$26B
$1.17M 0.32%
3,627
-1,400
-28% -$379K
2 3
4
5 6

Similar funds

RWM
Revisor Wealth Management Akron, Ohio $362M AUM 15.97% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MSL
MILLINGTON SECURITIES, LLC Red Bank, New Jersey $362M AUM
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
CAP
Cordoba Advisory Partners New York $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return

HighVista Strategies's Q1 2026 Portfolio in Review

As of Q1 2026, HighVista Strategies held 180 positions worth $362M, down 6.7% from $388M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $33.3M in Q1 2026, closing 24 positions and reducing 71 holdings. Its most notable exit was Cidara Therapeutics, an estimated $5.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Nurix Therapeutics worth $3.51M.

  • HighVista Strategies's largest Q1 2026 buy was Nurix Therapeutics: 226,546 shares worth $3.51M.
  • HighVista Strategies added most to Abivax in Q1 2026, an estimated $4.86M increase.
  • HighVista Strategies's biggest Q1 2026 reduction was Viridian Therapeutics, cutting an estimated $7.08M.
  • HighVista Strategies fully exited Cidara Therapeutics in Q1 2026, selling an estimated $5.06M.
  • HighVista Strategies's ten largest holdings make up 27% of its $362M portfolio in Q1 2026.
  • HighVista Strategies opened 35 new positions and closed 24 in Q1 2026.
  • HighVista Strategies's portfolio value fell 6.7% quarter-over-quarter to $362M.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.